The main antiemetic drugs after chemotherapy are gastrofacial, dexamethasone and 5-hydroxytryptamine receptor antagonists, such as ondansetron, granisetron, toltesetron, etc. There is also a relatively new drug that is a substance P antagonist, such as aripitant. If the chemotherapy drug used is a low emetogenic chemotherapy drug, antiemetic treatment with dexamethasone or gastroflucan is sufficient. For moderately emetogenic chemotherapeutic agents, a diphtheric or triple combination regimen is often recommended, such as 5-hydroxytryptamine receptor antagonist combined with dexamethasone, or 5-hydroxytryptamine receptor antagonist combined with dexamethasone and aripitant. Highly emetogenic anticancer drugs generally require a three-drug combination regimen, such as a 5-hydroxytryptamine receptor antagonist in combination with dexamethasone and aripitant.